Loading…
National Biotechnology Initiative Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
97pct
344d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2026 · third_quarter · Health Issues
Committee on Health, Education, Labor, and Pensions. Hearings held.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First
Client expense: $1,530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Science/Technology
Engaged with Members of Congress, congressional staff, and federal policymakers on biotechnology, artificial intelligence, and emerging technology policy issues. Discussed federal biotechnology initiatives, including recommendations of the National Security Commission on Emerging Biotechnology, the National Biotechnology Initiative Act of 2025 (S. 1387), and potential biotechnology provisions under consideration in the National Defense Authorization Act. Also provided briefings and demonstrations regarding advanced artificial intelligence capabilities and their potential applications in food, agriculture, research, manufacturing, and innovation; conducted follow-up engagements with congressional offices regarding these technologies; and hosted federal officials and Members of Congress to discuss biotechnology innovation, advanced manufacturing, workforce development, and U.S. competitiveness.
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Science/Technology
H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 H.R.1604/S.754, Farm and Food Cybersecurity Act H.R.2109/S.1018, The Cybersecurity for Rural Water Systems Act of 2025 Issues related to biotechnology research, development, and manufacturing
Client expense: $140,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2026 · third_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235); Cloud Labs to Advance Biotechnology Act of 2025 (S. 2676); Homestake AI Act of 2026 (S. 4991).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Manufacturing
biomanufacturing and technology S.4781 - Make More in America Act of 2026 S.1387 - National Biotechnology Initiative Act of 2025 H.R.2756 - National Biotechnology Initiative Act of 2025
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Science/Technology
biomanufacturing and technology S.4781 - Make More in America Act of 2026 S.1387 - National Biotechnology Initiative Act of 2025 H.R.2756 - National Biotechnology Initiative Act of 2025
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Agriculture
Issues related to sustainability, animal feed additives, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, biological products in agriculture, biotechnology and biological products, including the National Biotechnology Initiative Act of 2025 (H.R. 2756/S. 1387), and issues related to dietary supplements including H.R. 7366, the Dietary Supplement Regulatory Uniformity Act. Issues related to nutrition, FDA regulation of feed ingredients, and agricultural biotechnology.
Client expense: $140,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Manufacturing
H.R. 2756: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing H.R. 8800: National Defense Authorization Act for Fiscal Year 2027; provisions related to biomanufacturing S. 1387: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing S. ____: National Defense Authorization Act, 2027; provisions related to biomanufacturing P.L. 119-60 (S. 1071): National Defense Authorization Act for Fiscal Year 2026; provisions related to biomanufacturing Discussions related to biomanufacturing, and supply chain for amino acids and vitamins
Client expense: $1,500,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
2026 · second_quarter · Science/Technology
H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 H.R.1604/S.754, Farm and Food Cybersecurity Act H.R.2109/S.1018, The Cybersecurity for Rural Water Systems Act of 2025 Issues related to biotechnology research, development, and manufacturing
Client expense: $140,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2026 · second_quarter · Science/Technology
Engaged federal lawmakers on the CHIPs Act and Biotechnology, including recommendations from the National Security Commission on Emerging Biotechnology and the National Biotech Initiative Act of 2025, S. 1387
Client expense: $160,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235); Cloud Labs to Advance Biotechnology Act of 2025 (S. 2676);
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Manufacturing
biomanufacturing and technology S.4781 - Make More in America Act of 2026 S.1387 - National Biotechnology Initiative Act of 2025 H.R.2756 - National Biotechnology Initiative Act of 2025
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Science/Technology
biomanufacturing and technology S.4781 - Make More in America Act of 2026 S.1387 - National Biotechnology Initiative Act of 2025 H.R.2756 - National Biotechnology Initiative Act of 2025
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Manufacturing
H.R. 2756: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing S. 1387: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing P.L. 119-60 (S. 1071): National Defense Authorization Act for Fiscal Year 2026; provisions related to biomanufacturing Discussions related to biomanufacturing, and supply chain for amino acids and vitamins Discussions related to biomanufacturing and competitiveness of U.S. production of animal feed ingredients
Client expense: $2,050,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
2026 · first_quarter · Science/Technology
H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 S.3597, National Quantum Initiative Reauthorization Act of 2026 Issues related to biotechnology research, development, and manufacturing
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235); Cloud Labs to Advance Biotechnology Act of 2025 (S. 2676);
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Agriculture
Issues related to sustainability - no specific legislation. Issues related to animal feed additives, sustainability, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, and biological product in agriculture - no specific legislation. Issues related to biotechnology and biological products including H.R.2756/S.1387 - National Biotechnology Initiative Act of 2025. H.R. 7366 - Dietary Supplement Regulatory Uniformity Act - Issues related to dietary supplements.
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Manufacturing
H.R. 2756: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing S. 1387: National Biotechnology Initiative Act of 2025; provisions related to biomanufacturing P.L. 119-60 (S. 1071): National Defense Authorization Act for Fiscal Year 2026; provisions related to biomanufacturing Discussions related to biomanufacturing, and supply chain for amino acids and vitamins
Client expense: $1,320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, White House Office
2025 · fourth_quarter · Science/Technology
H.R.1604/S.754, Farm and Food Cybersecurity Act H.R.2109/S.1018, The Cybersecurity for Rural Water Systems Act of 2025 H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 Issues related to biotechnology research, development, and manufacturing
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Agriculture
Issues related to sustainability - no specific legislation. Issues related to animal feed additives, sustainability, renewable fuels, Generally Recognized as Safe (GRAS) Notification Program, and biological product in agriculture - no specific legislation. Issues related to biotechnology and biological products including H.R.2756/S.1387 - National Biotechnology Initiative Act of 2025. Issues related to dietary supplements - no specific legislation.
Client expense: $150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Science/Technology
H.R.1604/S.754, Farm and Food Cybersecurity Act H.R.2109/S.1018, The Cybersecurity for Rural Water Systems Act of 2025 H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 Issues related to biotechnology research, development, and manufacturing (David Sean McClintock only lobbied the U.S. House of Representatives)
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Science/Technology
H.R.1604/S.754, Farm and Food Cybersecurity Act H.R.2109/S.1018, The Cybersecurity for Rural Water Systems Act of 2025 H.R.2756/S.1387, National Biotechnology Initiative Act of 2025 Issues related to biotechnology research, development, and manufacturing (David Sean McClintock only lobbied the U.S. House of Representatives)
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Science/Technology
Risky Research Review Act (H.R. 1864, S. 854); National Biotechnology Initiative Act (H.R. 2756/ S. 1387); EPIC Act (H.R. 2582/ S. 1235).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE